根据这项会议的报道,在叶酸受体α(FRalpha)高、铂耐药卵巢癌患者中进行的III期MIRASOL(GOG3045/ENGOT-ov55)试验的事后分析显示,与研究者选择的化疗相比,即使是那些需要调整治疗剂量的患者,使用抗体-药物偶联物(ADC)mirvetuximab soravtan...
根据这项会议的报道,在叶酸受体α(FRalpha)高、铂耐药卵巢癌患者中进行的III期MIRASOL(GOG3045/ENGOT-ov55)试验的事后分析显示,与研究者选择的化疗相比,即使是那些需要调整治疗剂量的患者,使用抗体-药物偶联物(ADC)mirvetuximab soravtansine(MIRV)也获得了具有临床意义的疗效和生存改善(摘要#44O)。MIRASOL试验的...
1. Konecny GE, Moore KN, Lebreton C, et al. Patient-reported outcome results from phase III MIRASOL trial of mirvetuximab soravtansine versus investigator's choice of chemotherapy in FRα-positive, platinum-resistant ovarian cancer. Presented at: Society of Gynecologic Oncology 2024 Annual Meet...
5580#Background:Mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor alpha (FRα), demonstrated an improvement in progression-free survival (PFS), overall response rate (ORR), and overall survival (OS) in patients (pts) with high-grade serous PROC compared ...
Mirvetuximab soravtansine (MIRV)是一种靶向FRa的抗体偶联药物,在之前报道的单臂试验中证明了具有临床意义的抗肿瘤活性(Matulonis, JCO 2023)。MIRASOL是一项随机3期试验,旨在确认MIRV与标准的化疗相比,对铂耐药复发卵巢癌(PROC)患者(pts)的疗效...
doi:10.1016/j.annonc.2024.08.807L. Gardner CoffmanB. YouE.P. HamiltonY. Garcia GarciaK.N. MooreD. SonnenburgG. ScambiaS. DerioJ. Thomes PepinD. Klasa-MazurkiewiczAnnals of Oncology
Gottfried KonecnyUniversity of California, Los Angeles, Los Angeles, CA, United StatesKathleen MooreUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, United StatesCoriolan LebretonInstitut Bergonié, Bordeaux, FranceSaravut Weroha
根据这项会议的报道,在叶酸受体α(FRalpha)高、铂耐药卵巢癌患者中进行的III期MIRASOL(GOG3045/ENGOT-ov55)试验的事后分析显示,与研究者选择的化疗相比,即使是那些需要调整治疗剂量的患者,使用抗体-药物偶联物(ADC)mirvetuximab soravtansine(MIRV)也获得了具有临床意义的疗效和生存改善(摘要#44O)。MIRASOL试验的...